title: Rejection of adenovirus infection is independent of coxsackie and adenovirus receptor expression in cisplatin-resistant human lung cancer cells.
abstract: The adenovirus vector-based cancer gene therapy is controversial. Low transduction efficacy is believed to be one of the main barriers for the decreased expression of coxsackie and adenovirus receptor (CAR) on tumor cells. However, the expression of CAR on primary tumor tissue and tumor tissue survived from treatment has still been not extensively studied. The present study analyzed the adenovirus infection rates and CAR expression in human lung adenocarcinoma cell line A549 and its cisplatin-resistant subline A549/DDP. The results showed that although the CAR expression in A549 and A549/DDP was not different, compared with the A549, A549/DDP appeared obviously to reject adenovirus infection. Moreover, we modified CAR expression in the two cell lines with proteasome inhibitor MG-132 and histone deacetylase inhibitor trichostatin A (TSA), and analyzed the adenovirus infection rates after modifying agent treatments. Both TSA and MG-132 pretreatments could increase the CAR expression in the two cell lines, but the drug pretreatments could only make A549 cells more susceptible to adenovirus infectivity.
authors.affiliation: Department of Oncology, Guangdong Second Provincial Traditional Chinese Medicine Hospital, Guangzhou, Guangdong 510095, P.R. China.
authors.forename: Nian-Hua
authors.initials: NH
authors.lastname: Zhang
authors.affiliation: State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, P.R. China.
authors.forename: Rui-Qing
authors.initials: RQ
authors.lastname: Peng
authors.affiliation: State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, P.R. China.
authors.forename: Ya
authors.initials: Y
authors.lastname: Ding
authors.affiliation: State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, P.R. China.
authors.forename: Xiao-Shi
authors.initials: XS
authors.lastname: Zhang
mesh_terms: D000072283:A549 Cells; D000230:Adenocarcinoma / Q000188:drug therapy / Q000235:genetics* / Q000821:virology; D000077192:Adenocarcinoma of Lung; D000256:Adenoviridae / Q000187:drug effects; D000257:Adenoviridae Infections / Q000188:drug therapy / Q000235:genetics* / Q000821:virology; D045744:Cell Line, Tumor; D002945:Cisplatin / Q000494:pharmacology*; D062727:Coxsackie and Adenovirus Receptor-Like Membrane Protein / Q000235:genetics*; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D056572:Histone Deacetylase Inhibitors / Q000494:pharmacology; D006801:Humans; D006877:Hydroxamic Acids / Q000494:pharmacology; D007976:Leupeptins / Q000494:pharmacology; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000821:virology; D061988:Proteasome Inhibitors / Q000494:pharmacology
chemical_list: D062727:Coxsackie and Adenovirus Receptor-Like Membrane Protein; D056572:Histone Deacetylase Inhibitors; D006877:Hydroxamic Acids; D007976:Leupeptins; D061988:Proteasome Inhibitors; C012589:trichostatin A; D002945:Cisplatin; C072553:benzyloxycarbonylleucyl-leucyl-leucine aldehyde